Evaluation of Prolonged Antithrombotic Pretreatment (" Cooling-off" Strategy) before Intervention in Patients with Unstable Coronary Syndromes: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 12, 2003, Pages 1593-1599

  Neumann, Franz Josef ^a,b   Kastrati, Adnan ^a   Pogatsa Murray, Gisela ^a   Mehilli, Julinda ^a   Bollwein, Hildegard ^a   Bestehorn, Hans Peter ^b   Schmitt, Claus ^a   Seyfarth, Melchior ^a   Dirschinger, Josef ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TIROFIBAN; TROPONIN T; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; TICLOPIDINE; TYROSINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DEATH; FEMALE; GERMANY; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ANGINA PECTORIS; BLOOD; CATHETERIZATION; METHODOLOGY; MIDDLE AGED; PREOPERATIVE CARE; RISK; STENT;

AGED; ANGINA PECTORIS; ASPIRIN; CATHETERIZATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PREOPERATIVE CARE; RISK; STENTS; TICLOPIDINE; TREATMENT OUTCOME; TROPONIN T; TYROSINE;

EID: 0141797306     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.12.1593     Document Type: Article

References (29)

1. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708-715.
2. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet. 2000;356:9-16.
3. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
4. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. 2002;360:743-751.
5. Bjessmo S, Ivert T, Flink H, Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class. Am Heart J. 2001;141:9-14.
6. Boden W, O'Rourke R, Crawford M, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as com-pared with a conservative management strategy. N Engl J Med. 1998;338:1785-1792.
7. de Feyter PJ, van den Brand M, Laarman GJ, van Domburg R, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation. 1991;83:927-936.
8. Schühlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104-111.
9. de Feyter P. Percutaneous coronary intervention for unstable angina. In: Topol E, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders; 1999:244.
10. Laskey MA, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol. 1990;65:1425-1429.
11. Laskey MA, Deutsch E, Hirshfeld JW Jr, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol. 1990;65:179-182.
12. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed February 16, 2003.
13. Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIta receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial. Circulation. 1999;100:1609-1615.
14. van den Brand M, Laarman GJ, Steg PG, et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients: angiographic results from the CAPTURE trial. Eur Heart J. 1999;20:1572-1578.
15. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
16. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
17. Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation. 2002;105:2347-2354.
18. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 2001;103:3019-3041.
19. Müller I, Seyfarth M, Rüdiger S, et al. Effect of high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-93.
20. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
21. Berger VW. Improving the information content of categorical clinical trial endpoints. Control Clin Trials. 2002;23:502-514.
22. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730-735.
23. Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv. 2002;55:436-441.
24. Kastrati A, Mehilli J, Schühlen H, et al. A double-blind, placebo-controlled, randomized trial evaluating the glycoprotein IIb/IIIa inhibitor abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Presented at: Late-Breaking Trial Session of the 75th Annual Scientific Sessions of the American Heart Association; November 17-20, 2002; Chicago, Ill.
25. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schömig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol. 2001;37:1323-1328.
26. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
27. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045-2048.
28. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
29. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.